Semaglutide vs. Retatrutide: Where Metabolic Peptides Stand in 2026

Five years ago, the idea that a medication could help people lose a fifth of their body weight sounded like hype. Now it’s in the published trial data.

Semaglutide made the GLP-1 class famous. Tirzepatide raised the bar. Retatrutide, a triple agonist, has now posted Phase 3 results that go further still. Here’s how they work, what the data actually says, who they’re meant for, and why the scale is the wrong way to judge your progress on any of them.

Three Generations, One Idea

All three drugs mimic gut hormones that help regulate appetite and blood sugar. The difference is how many hormone pathways each one targets.

GLP-1 (semaglutide). GLP-1 is released after you eat. It boosts insulin in a glucose-dependent way, lowers glucagon, slows stomach emptying and reduces appetite in the brain. Semaglutide is engineered to last much longer than the natural hormone.

GIP plus GLP-1 (tirzepatide). Adding a second gut hormone, GIP, produced larger average weight loss in trials.

GIP plus GLP-1 plus glucagon (retatrutide). Glucagon raises blood sugar, which sounds like the opposite of what you’d want. But it also increases energy expenditure and fat breakdown. Balanced against the other two signals, the result in trials has been even more weight loss.

What the Trials Show

Here’s the headline data, described by “highest dose tested” rather than amounts, because dosing is a decision for your prescriber, not a blog.

Semaglutide. In the STEP 1 trial, Wilding et al. (2021) reported average weight loss of 14.9% at 68 weeks, versus 2.4% on placebo. In people with existing cardiovascular disease and overweight or obesity, the SELECT trial found semaglutide reduced major cardiovascular events by 20% compared with placebo.

Tirzepatide. In SURMOUNT-1, Jastreboff et al. (2022) reported average weight loss of up to 20.9% at 72 weeks, versus 3.1% on placebo.

Retatrutide, Phase 2. The 2023 trial by Jastreboff et al. showed 24.2% average weight loss at 48 weeks on the highest dose. It also noted dose-dependent heart rate increases that peaked at 24 weeks and then declined.

Retatrutide, Phase 3. This is the new part. In TRIUMPH-1, published in 2026 with 2,339 participants, average weight loss was 25.0% on the highest dose tested versus 3.9% on placebo, with gastrointestinal side effects the most common. Participants with knee osteoarthritis also saw reduced pain, and those with sleep apnea had fewer events per hour. Lilly has reported that two further Phase 3 trials, TRIUMPH-2 and TRIUMPH-3, also met their goals, and TRIUMPH-2 has since been published in The Lancet.

Retatrutide is still not approved. Lilly has said it plans to file for approval, but until FDA acts, anything sold as retatrutide comes from outside the approved supply chain.

The Pill Era Has Started

An earlier version of this post called an oral semaglutide “oral Ozempic.” That was wrong, and the landscape has changed anyway.

In December 2025, FDA approved the Wegovy pill, an oral semaglutide for weight management. In April 2026, it approved Foundayo (orforglipron), Lilly’s non-peptide oral GLP-1 drug. Oral options mean more choice. They don’t change the core tracking advice below.

Who These Drugs Are For

The approved GLP-1 drugs for weight management are prescription medicines for adults with obesity, or with overweight plus a weight-related health condition. A prescriber decides who qualifies.

Some people should be especially careful or avoid them entirely. According to MedlinePlus, semaglutide injection carries an important warning: it caused thyroid tumors in rats, and people with a personal or family history of thyroid cancer or multiple endocrine neoplasia type 2 (MEN 2) will usually be told not to use it. Pancreatitis and gallbladder problems are among the other risks to discuss.

FDA has also warned about compounded and counterfeit semaglutide, including dosing errors and products that aren’t what they claim to be.

If you’re metabolically healthy and thinking about these drugs for a cut, be honest with yourself about the trade-off. They’re powerful medicines with real side effects, not performance supplements.

The Lean Mass Question

This is the part most people miss. Losing weight fast isn’t the same as losing fat.

A 2024 review by Neeland et al. found that in some GLP-1 trials, lean mass made up 40% to 60% of the total weight lost, while in others it was about 15% or less. It also stressed that lean mass isn’t the same as muscle. Either way, the takeaway is clear: if you only track weight, you can’t tell good progress from bad.

What helps protect muscle? Resistance training, and enough protein. A meta-analysis by Morton et al. (2018) found protein supplementation boosted strength and muscle gains from resistance training. Ask your clinician or a dietitian what protein target makes sense for you, especially if your appetite drops a lot.

What Happens When You Stop

This is one of the most important and least discussed facts about these drugs. For most people, they work while you take them.

In the STEP 4 trial, Rubino et al. (2021) gave everyone semaglutide for 20 weeks, then randomly switched some participants to placebo. Over the following 48 weeks, those who continued lost a further 7.9% of their body weight on average, while those switched to placebo regained 6.9%.

The STEP 1 extension tells a similar story. When Wilding et al. (2022) followed participants for a year after treatment ended, they had regained two-thirds of the weight they’d lost on average, and the improvements in cardiometabolic risk factors largely reverted.

That doesn’t make the drugs pointless. It means they’re best thought of as a long-term treatment, like blood pressure medication, rather than a short course. If you’re planning to stop, or can’t keep paying for them, talk to your prescriber about what comes next. And it’s another reason to protect muscle while you’re on them: the habits you build, like resistance training and enough protein, are the part you keep.

Side Effects Worth Writing Down

Gastrointestinal side effects are the most common. In STEP 4, they were reported by 49.1% of people who continued semaglutide versus 26.1% on placebo. Most people never need to do more than mention them at their next appointment, but a simple log makes that conversation far more useful than “I felt sick sometimes.”

Worth noting each day, briefly:

• Nausea, vomiting, diarrhea or constipation, and how bad on a simple scale
• Appetite and roughly how much you managed to eat, especially protein
• Fluids, since reduced appetite can mean reduced drinking too
• Energy and any dizziness

MedlinePlus advises telling your doctor if common side effects like nausea or stomach pain are severe or don’t go away. Some symptoms shouldn’t wait at all. Ongoing pain that starts in the upper left or middle of the stomach and may spread to the back, with or without vomiting, is on its list of symptoms that need an immediate call to your doctor or emergency care, along with signs of an allergic reaction, a rapid or pounding heartbeat and vision changes. If in doubt, call.

How to Track It

If you’re on one of these medications under medical supervision, here’s what’s worth logging:

Side effects and appetite. A quick daily note on nausea, GI symptoms and appetite gives your prescriber something concrete to work with. Don’t change your dose or schedule on your own based on it.

Body composition, not just weight. Waist measurements, consistent photos and scans tell you what the scale can’t. Our post on why the scale lies goes deeper.

Strength. If your lifts are holding steady while weight drops, that’s a good sign. If they’re falling off a cliff, raise it with your clinician.

Blood work. HbA1c, fasting glucose, lipids and a metabolic panel at intervals your clinician sets. Our guide to blood panels covers how to keep results comparable.

Resting heart rate. Worth watching, given the heart rate increases seen with retatrutide in trials.

In Pinnacle Pulse, you can log all of this next to each other, so when you see your prescriber, you’re bringing a trend line instead of a feeling.

A Worked Example (Illustrative)

Here’s a fictional example of the kind of record that helps. The person and numbers are invented.

Maria starts prescribed semaglutide for obesity. Before starting, she records her weight as a weekly average, a waist measurement, photos, and her baseline strength on three lifts she does twice a week. Her prescriber orders baseline blood work.

In the first two months, her weekly average weight drops steadily. Her nausea log shows the worst days cluster after large, fatty meals, which she mentions to her prescriber, who suggests smaller meals. Her protein intake, which she logs roughly, has fallen a lot because she simply isn’t hungry.

At month three, her weight is down, her waist is down, but two of her three lifts have dropped noticeably. Without that data, she’d have seen only the scale and felt great. With it, she and her prescriber, and later a dietitian, focus on protein at each meal and keeping her lifting sessions consistent.

By month six, her lifts have recovered most of the lost ground while her waist keeps shrinking. Her blood work shows HbA1c improved. The scale shows a slower loss than at the start, which on its own might have worried her. Her full record shows the loss is now more likely to be fat.

Common Mistakes

Tracking only weight. As the lean mass data shows, you can’t judge the quality of the loss from the scale.

Under-eating protein because you aren’t hungry. Appetite suppression is the point of the drug, but it makes protein easy to neglect.

Stopping resistance training. Fatigue and smaller meals make it tempting to skip. It’s the main thing protecting your muscle.

Adjusting on your own. Skipping, doubling or changing timing because of side effects is a conversation for your prescriber.

Buying from unofficial sources. FDA has warned about counterfeit and compounded products with dosing errors and wrong contents.

Assuming the results are permanent. The STEP 4 and STEP 1 extension data say otherwise for most people. Plan with your prescriber.

Questions for Your Prescriber

1. Am I a good candidate, given my history, including thyroid and pancreas history?
2. Which side effects should I expect, and which mean I should call you?
3. What should my protein and training look like while I’m on this?
4. Which blood tests will we track, and how often?
5. What’s the plan if I want to stop, or can’t continue for cost reasons?

What’s Next

The pipeline is busy: more oral options, more combination drugs, and a growing focus on preserving muscle during weight loss. Expect the retatrutide approval decision to be the big story of 2027.

Whatever comes next, the principle stays the same. The number on the scale is the least interesting thing to track. What it’s made of is what matters. For the bigger picture on peptides and how they’re regulated, see What Are Peptides?.

This article is for educational purposes only and is not medical advice. Semaglutide, tirzepatide and orforglipron are prescription medicines; retatrutide is investigational. Only take them under the care of a licensed prescriber.

FAQ

Is retatrutide FDA-approved?

No. As of October 2026, retatrutide is still investigational. Lilly has reported positive Phase 3 results and said it plans to submit for approval, but anything sold as retatrutide today is not an approved product.

How much weight did people lose on retatrutide in Phase 3?

In the TRIUMPH-1 trial, published in 2026, participants on the highest dose tested lost an average of 25.0% of their body weight, compared with 3.9% on placebo.

Is all the weight lost on GLP-1 drugs fat?

No. A 2024 review found that in some trials lean mass made up 40% to 60% of total weight lost, while in others it was about 15% or less. That's why tracking body composition, not just weight, matters.